Skip to content

INOVIO PHARMACEUTICALS, INC.: 10-K filed 2012-03-15

What INOVIO PHARMACEUTICALS, INC. reported in its annual report filed 2012-03-15 (fiscal FY 2011): 35 published measures, 91 facts as tagged in accession 0001193125-12-117292.

This filing

Form
10-K (annual report)
Filed
2012-03-15
Fiscal period
fiscal FY 2011
Accession
0001193125-12-117292 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All INOVIO PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-12-3161,106,561USD
At 2010-12-3156,067,391USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-12-3113,244,899USD
At 2010-12-318,966,480USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-12-3147,314,894USD
At 2010-12-3146,502,993USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-12-3117,350,116USD
At 2010-12-3119,998,489USD
At 2009-12-3130,296,215USD
At 2008-12-3114,115,281USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-15,252,945USD365
2010-01-01 to 2010-12-31-17,613,796USD365
2009-01-01 to 2009-12-31-24,411,485USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-19,755,717USD365
2010-01-01 to 2010-12-31-11,937,528USD365
2009-01-01 to 2009-12-31-14,080,192USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-01-01 to 2011-12-31161,187USD365
2010-01-01 to 2010-12-31181,649USD365
2009-01-01 to 2009-12-3148,368USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2011-01-01 to 2011-12-319,795,257USD365
2010-01-01 to 2010-12-316,144,705USD365
2009-01-01 to 2009-12-319,120,111USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-12-3128,010,531USD365
2010-01-01 to 2010-12-31-9,693,123USD365
2009-01-01 to 2009-12-3128,604,255USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-10,899,924USD365
2010-01-01 to 2010-12-3111,435,871USD365
2009-01-01 to 2009-12-311,446,345USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-12-31-210,091,174USD
At 2010-12-31-194,838,229USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-12-31295,785USD
At 2010-12-31276,795USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-01-01 to 2011-12-311,654,823USD365
2010-01-01 to 2010-12-311,174,867USD365
2009-01-01 to 2009-12-312,157,879USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-21,638,540USD365
2010-01-01 to 2010-12-31-19,220,162USD365
2009-01-01 to 2009-12-31-13,957,755USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-12-3131,907,086USD
At 2010-12-3122,877,207USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-12-3111,043,021USD
At 2010-12-316,436,708USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2011-12-3110,113,371USD
At 2010-12-3110,113,371USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2011-12-31467,909USD
At 2010-12-3132,887USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-01-01 to 2011-12-3131,433,797USD365
2010-01-01 to 2010-12-3125,364,867USD365
2009-01-01 to 2009-12-3123,077,866USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-01-01 to 2011-12-3120,032,001USD365
2010-01-01 to 2010-12-3113,256,606USD365
2009-01-01 to 2009-12-319,408,457USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-12-31134,968,394shares
At 2010-12-31105,038,192shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-12-31257,235,707USD
At 2010-12-31241,233,334USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2011-12-3135,393USD
At 2010-12-312,850USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2011-12-3147,861,662USD
At 2010-12-3147,100,911USD
At 2009-12-3161,184,947USD
At 2008-12-3119,106,147USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2011-12-319,310,485USD
At 2010-12-3111,180,002USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-12-31208,262USD
At 2010-12-31259,128USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2011-12-311,059,372USD
At 2010-12-31178,328USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-12-31746,049USD
At 2010-12-31273,975USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-15,304,095USD365
2010-01-01 to 2010-12-31-17,638,746USD365
2009-01-01 to 2009-12-31-24,458,924USD365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-15,271,552USD365
2010-01-01 to 2010-12-31-17,741,692USD365
2009-01-01 to 2009-12-31-24,359,287USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-3111,988,796USD365
2010-01-01 to 2010-12-3112,108,261USD365
2009-01-01 to 2009-12-3113,669,409USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2011-01-01 to 2011-12-31142,197USD365
2010-01-01 to 2010-12-31194,629USD365
2009-01-01 to 2009-12-31237,222USD365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2011-01-01 to 2011-12-311,869,517USD365
2010-01-01 to 2010-12-311,913,912USD365
2009-01-01 to 2009-12-311,439,756USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-01-01 to 2011-12-3127,994,601USD365
2010-01-01 to 2010-12-312,314,124USD365
2009-01-01 to 2009-12-3128,406,356USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31435,022USD365
2010-01-01 to 2010-12-31-226,320USD365
2009-01-01 to 2009-12-31-288,155USD365

Inspect the source

Entity
INOVIO PHARMACEUTICALS, INC. / CIK 0001055726
Captured
2026-09-20T05:17:43.559Z
SEC response SHA-256
9bfa830827e08b2d190e6d0b4ce0274a3c0d8852b6e536b16b5cfeadcaa54cf9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001055726.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))